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Abstract
Clostridium difficile colitis is an infection that causes inflammation of the colon and
diarrhea. This can even lead to death in some cases. The incidence of this infection and its
overall effects have been on the rise throughout the last twenty years as antibiotics have been
prescribed more frequently. Therefore, it is necessary that the rate of C. difficile infection is
lowered by improved guidelines for hospitals, so that fewer people are infected and also that
fewer antibiotics are prescribed to avoid the infection with C. difficle.
What is Clostridium difficile colitis?
C. difficile is a gram positive, anaerobic, spore forming bacterium that has the ability to
produce exotoxins that cause colitis in humans (Salyers et al., 1994). It is estimated that
approximately 5% of the population naturally have C. difficile present as part of their intestinal
microbiota (Wilson et al., 2011). When C. difficile becomes pathogenic due to many different
factors, including suppression of natural microbiota due to antibiotics, C. difficile can cause
colitis. The growth of the bacteria is due to the fact that the niches that the normal microbiota fill
are no longer inhabited and C. difficile is able to exploit this uninhabited niche and the spores can
germinate. This in turn can cause C. difficile colitis.
C. difficile virulence factors
The first step in the pathogenicity of C. difficile colitis is the attachment of the bacterium
to the mucus and cells that line the colon (Wilson et al., 2011). The toxins that C. difficile
produces are able to damage the colonic mucosa, and the symptoms include the production of
yellowish layer on the surface of the colon made up of fibrin, mucin, and dead host cells (Wilson
et al., 2011). This damage causes an inflammatory response in the body and neutrophils are
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recruited (Wilson et al., 2011). Once the yellowish layers of several different areas converge
together, it is called a pseudomembrane (Wilson et al., 2011).
C. difficile that causes this pseudomembrane has the ability to produce two large AB-type
protein toxins, toxin A (TcdA) and toxin B (TcdB) (Wilson et al., 2011). These toxins work by
modifying the G proteins of host’s cell membranes that control many cellular activities, one of
these is actin polymerization (Wilson et al., 2011). TcdA works by causing the mucosal cells to
become so filled with fluid that they are no longer able to control water movement (Wilson et al.,
2011). TcdB collapses the actin cytoskeleton of tissue culture cells (Wilson et al., 2011). Also,
TcdA works more slowly than TcdB which may account for why strains of C. difficile colitis that
only produce TcdB are still able to cause damage (Wilson et al., 2011).
TcdA Mechanism
TcdA stimulates intestinal mucosal cells which produce cytokines and inflammatory
proteins (Wilson et al., 2011). This attracts neutrophils (polymorphonuclear cells [PMNs])
creating a large inflammatory response (Wilson et al., 2011). Response of this magnitude results
in mucosal cell destruction (Wilson et al., 2011). The neutrophils move between the cells to
reach the area of infection, which can cause the tight junctions to become damaged (Wilson et
al., 2011). This damage causes water flow between the cells to be uncontrolled (Wilson et al.,
2011) This results in water to leak into the lumen of the intestine and for a pathway for TcdB to
enter (Wilson et al., 2011).
TcdA targets two G proteins (Wilson et al., 2011). G proteins are important because they
are responsible for many regulatory functions in mammals (Wilson et al., 2011). One of the
functions that they are responsible for is the control of the polymerization and depolymerization
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of actin (Wilson et al., 2011). With polymerization and depolymerization inhibited the actin
cytoskeleton is not able to change as it naturally does (Wilson et al., 2011). This results in
problems with neutrophil movement (Wilson et al., 2011).
TcdB Mechanism
TcdB gains access through the damage that TcdA causes (Wilson et al., 2011). Once
inside the mucosal membrane of the intestines, TcdB damages the tissue on the underside of the
mucosal membrane and intestinal wall (Wilson et al., 2011). Damage can become so extensive
that LPS or bacteria from the colon are able to enter into the bloodstream and this can result in
septic shock (Wilson et al., 2011).
How C. difficile may be transmitted
C. difficile is able to survive for extended periods of time through its spores. Therefore, it
is important, especially in a hospital setting for doctors, nurses, patients, and visitors to use
caution when working with a patient who has C. difficile colitis. Living bacteria or their spores
can be transmitted by environmental surface contamination, staff or infected patients (Surawicz
et al., 2013). Endospores are able to survive on surfaces for up to five months (Gerding et al.,
2015). This means that if surfaces are not disinfected correctly, C. difficile spores are able to be
transmitted up to five months after they were original deposited on the surface (Surawicz et al.,
2013).
Symptoms
There are several different stages of the disease that a patient may be experiencing (Shen
et al., 2008). Symptoms of a mild to moderate infection include watery diarrhea three or more
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times a day for two or more days and mild abdominal cramping and tenderness (Surawicz et al.,
2013). Symptoms of a more severe stage of the disease that a patient could notice on their own
without tests may include: watery diarrhea occurring anywhere from ten to fifteen times a day,
severe abdominal cramping and pain, fever, blood or pus in the stool, nausea, dehydration, loss
of appetite, weight loss, and/or swollen abdomen (Surawicz et al., 2013). The most severe stage
is defined as the patient being required to stay in an intensive care unit (ICU). An endoscopic
examination that shows the presence of pseudomembranes or the existence of two of more of the
following symptoms: patients is over 60 years old, experiencing a fever of over 38.3˚C, their
albumin level is less than 2.5mg/dL, or their white blood cell count within 48 hours of admission
is greater than 15,000/μL are indicators of severe stage (Shen et al., 2008).
Antibiotic Risk Factors
96% of people who have symptoms of C. difficile colitis were found to have received
antibiotic within the last 14 days before their first symptoms appeared (Cohen et al., 2010).
Furthermore, all patients with C. difficile colitis symptoms had received antibiotics within the
last 3 months (Cohen et al., 2013). Many outbreaks of C. difficile colitis are associated with the
use of fluoroquinolones (Cohen et al., 2013). While fluoroquinolones, which target DNA gyrase,
have been associated with a higher risk for the development of C. difficile colitis (Cohen et al.,
2013). This may be due fluoroquinolones being broad spectrum antibiotics. However, almost all
antibiotics have been associated with C. difficile colitis (Cohen et al., 2013). Fluoroquinolones
are broad spectrum antibiotics which causes them to be associated with a higher risk for the
development of C. difficile colitis.
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Also, it was discovered that the increased use of these antibiotic was associated with the
emergence of a new hypervirulent strain of C. difficile, strain BI/NAP1/027 (Shen et al., 2008).
Strain BI/NAP1/027 has been found in 67%-82% of illnesses in Quebec which led researchers to
believe that it may be transmitted with a higher effectiveness than other strains (Cohen et al.,
2013). This strain has an additional toxin, the binary toxin, which may account for its higher
transmission rates (Cohen et al., 2013). This strain has been shown to cause a more severe
disease in patients than those effected with other strains (Cohen et al., 2013).
Diagnostic Testing
Testing a patient quickly and accurately for C. difficile colitis is in the best interest of
both the patient and the doctor. There are several different methods for testing but the best
specimen for all testing methods is a watery, loose, or unformed stool that is promptly delivered
to the laboratory (Cohen et al., 2013). Due to cost and efficiency, antibody-based testing is the
preferred method of identifying the toxins (Cohen et al., 2013). These tests are also the easiest
for the laboratory to perform (Cohen et al., 2013).
Cell Cytotoxicity Assay
This assay is looking for the effects of C. difficile toxins on human cells that are grown in
culture (Cohen et al., 2013). Many laboratories use human foreskin fibroblast cells (Cohen et al.,
2013). These cells are the most sensitive cell line for detecting the toxin (Cohen et al., 2013).
This assay has a detection rate ranging from 67% to 100% (Cohen et al., 2013).
Enzyme Immunoassay (EIA)

6

EIA tests are designed to detect toxin A only or to detect both toxins A and B (Cohen et
al., 2013). However, it is preferred that both toxin A and B are tested for as 1%-2% of the strains
present in the United States do not produce toxin A (Cohen et al., 2013). Ninety percent of the
laboratories routinely use this test as it is easy to perform and cost effective (Cohen et al., 2013).
It also has been shown to have a sensitivity of 63%-94% with a specificity of 75%-100% (Cohen
et al., 2013).
Culture
Testing in this method is highly preferred in many laboratories and is essential to the
study of C. difficile (Cohen et al., 2013). When grown in a solid medium, the colonies are flat,
yellow, ground glass-appearing with a surrounding yellow halo (Cohen et al., 2013). They stain
as gram-positive bacteria. The agar that the bacterium is grown on must be selected carefully and
the plates must be incubated in an anaerobic environment (Cohen et al., 2013). Many
laboratories use this diagnosis for a patient carrying C. difficile colitis.
Glutamate dehydrogenase (GDH)
GDH is an enzyme that is produced by C. difficile (Surawicz et al., 2013). This enzyme is
produced in higher amounts compared to toxins A and B (Surawicz et al., 2013). C. difficile
produces a NAD-specific GDH that through an irreversible reaction converts L-glutamate into
alpha-ketoglutarate (Girinathan et al., 2013). This test is not highly sensitive even though it is a
rapid test that laboratories can perform (Cohen et al., 2013). Therefore, this is a test that should
be used in conjunction with another test (Cohen et al., 2013). If this test produces a negative
result, the patient is determined to not be infected (Cohen et al., 2013). However, if a positive
result is obtained, further confirmatory tests are performed (Cohen et al., 2013). This allows for
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an initial screening of patients to quickly rule out those who are not infected. GDH is routinely
coupled with a cell cytotoxin assay when a positive result is yielded (Cohen et al., 2013). This is
a cost saving mechanism that has saved between $5,700 and $18,100 per month (Cohen et al.,
2013).
Polymerase Chain Reaction (PCR)
This test is now considered the “gold standard” test for C. difficile. PCR works by
amplification of a DNA sequence. This allows the researcher to be able to easily identify a
specific part of the DNA through tagging it with another sequence. This other sequence is
normally some sort of sequence that under UV light is fluorescent allowing it to be easily
detected. In the case of C. difficile the person running the test is able to selectively tag for TcdA
and TcdB sequences (Belanger et al., 2003). This test is a diagnostic test that is simple and takes
approximately an hour to complete (Belanger et al., 2003).
Current Treatment Options
Antibiotics
In order to successfully treat C. difficile colitis, it is important to have an early diagnosis.
The cause that leads to this illness is usually an antibiotic treatment and this must be
discontinued as quickly as possible (Cohen et al., 2013). Once the original treatment is stopped
an antibiotic treatment including metronidazole or vancomycin are used to treat the C. difficile
colitis (Salyers et al., 1994). Metronidzole is the drug of choice for someone experiencing their
first case of C. difficile colitis (Cohen et al., 2013). Patients are given 500 mg orally 3 times per
day for 10-14 days (Cohen et al., 2013). Vancomycin is dosed as 125 mg orally 4 times per day
for 10-14 days (Cohen et al., 2013). The use of vancomycin is normally reserved for a patient
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with a severe case of the disease (Cohen et al., 2013). While orally is the administration of
choice, the antibiotics can be administered in one of three different ways: oral, rectal, or
intravenously (IV) (Shen et al., 2008).
Fidaxomicin, commonly known as Dificid, is another antibiotic that was approved for use
to treat C. difficile colitis in May of 2011 by the FDA (Cruz, 2012). However, it should only be
used in cases that are caused by C. difficile in order to avoid the possible development of an
antibiotic-resistance bacterium (Cruz, 2012). This drug works through the inhibition of RNA
polymerases (Cruz, 2012). This results in the bacterium not being able to carry out RNA
transcription. Dificid acts directly in the GI tract on C. difficile (Cruz, 2012). It has been given
for 10 days at a dosage of 200 mg twice daily (Cruz, 2012).
Colectomy
There are cases when the disease is so severe that an alternate approach is taken. A
colectomy is suggested for these patients (Cohen et al., 2013). However, this patient must have
their serum lactate level and peripheral blood white blood cell count monitored to ensure they
will be able to survive the surgery (Cohen et al., 2013). The postoperative mortality rate is 75%
or higher when the lactate level of a patient is greater or equal to 5mmol/L (Cohen et al., 2013).
Fecal microbiota transplantation (FMT)
FMT is the process of delivering stool from a healthy donor into a patient (Bowman et
al., 2015). The donor can be a spouse, close relative, or any healthy unrelated donor (Bowman et
al., 2015). However, it has been shown that the first choice should be to receive the stool from
someone who is genetically related to the patient (Bowman et al., 2015). The routes of
administration are enema, colonoscopy, or by the upper gastrointestinal (GI) tract via ingestion
9

(Bowman et al., 2015). This method of treatment is preferred due to the decrease in probability
that a relapse of C. difficile colitis will occur due to changes in the normal microbiota due to the
continued use of antibiotics (Bowman et al., 2015). The goal of this treatment is to help the body
reestablish its normal microbiota (Bowman et al., 2015). FMT restores the dominance of the
microbiota to Bacteroidetes and Firmicutes which are the bacteria phyla that dominate a healthy
gut (Bowman et al., 2015). It has been shown that this treatment option has an efficiency of 83%90% (Bowman et al., 2015). Also, it has been shown to be a great option for people with
compromised immune systems (Bowman et al., 2015). It allows them to receive relief from C.
difficile colitis without taking more antibiotics or drugs.
To administer the stool, it is mixed with a nonbacteriostatic saline solution and then
strained or blended to remove unwanted particulate (Bowman et al., 2015). If the solution is be
administered during a colonoscopy the solution is drawn up into a syringe and infused into the
colon (Bowman et al., 2015). The larger the amount administered appears to provide a more
effective treatment (Bowman et al., 2015). Greater than five-hundred mL of stool showed a 97%
resolution in patients while 200mL only showed an 80% improvement of patients (Bowman et
al., 2015).
After the treatment, the symptoms can subside and the patient can return to normal within
several days (Shen et al., 2008). However, approximately 10% - 20% of individuals will
experience a relapse of the illness (Salyers et al., 1994).
Why C. difficile Is a Concern
Not only is C. difficile a concern in regards to increasing antibiotic resistance and the
health of patients, or even their deaths, but it is compounded with the problem that it is costing
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approximately $3.2 billion annually (Surawicz et al., 2013). This is astounding as we are
currently in a period in our healthcare system where we are trying to reform it and make the
services more readily available to someone with any income level. This one area could be saving
patients billions of dollars each and every year. Also, if we are not able to gain control over this
disease, it is going to continue to increase the costs that patients are going to have to face.
Solutions
There are several approaches we can take to reduce the risk of C. difficile disease.
Education
The first step to creating a mind set to reduce the amount of antibiotics prescribed to
patients (Karras et al., 2003). Doctors sometimes prescribe antibiotics to patients simply because
they want to fulfill the perceived expectations of the patient (Karras et al., 2003). However, it has
been shown that about only 33% of the patients had any expectation that the physician was going
to prescribe them an antibiotic (Karras et al., 2003). This mentality of physician prescribing
antibiotics simply because of their perception of patient’s expectations needs to be curbed
through education in order to be the first step towards helping to eliminate the risk of C. difficile.
Also, in their education, doctors need to be informed about the risks that prescribing certain
antibiotics such as cephalosporins, clindamycin, and fluoroquinolones have in increasing the risk
for C. difficile.
Not only is education necessary for physicians but education of the effects of antibiotics
needs to be passed down to the patients as well. When physicians are getting ready to prescribe
the antibiotics that are known to be associated with causing C. difficile colitis, they need to
explain the risks to their patients. Patients have the right to know that the antibiotic they are
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being prescribed could lead to a hospital stay for them and in extreme cases could lead to death.
Patients deserve a brief education on the risks before they decide if taking the antibiotic is the
right choice for them. In some cases, a patient may have another treatment option or may be able
to wait a while longer and let their body continue to try and fight the infection off.
Prevention of transmission
Transmission is imperative so that the bacterium is not spread around the hospital to other
patients. One of the best ways to help reduce the spread of it is to increase the standard of
handwashing that physicians, nurses, and any other person coming into contact with an infected
patient are required to do.
Anyone coming into contact with the patient should use either hand-sanitizer or hand
washing before entering the patient’s room, and they must also wear gloves and a gown. This
will create a barrier between the physician and the patient that can be disposed of upon leaving
the room. The rate of transmission has decreased from 7.7 cases per 1,000 discharges to 1.5 cases
per 1,000 discharges in the United States since then institution of gloves (Cohen et al., 2010).
Also, whoever comes into contact with the patient will be required a rigorous
handwashing when exiting the patients room. It has been found that antibacterial soap is not any
more effective at reducing diarrhea causing bacteria from hand than normal soup (Burton et al.,
2011). Not being required to use antibacterial soap is good in the application of C. difficile due
this eliminating a possible pathway for increase antibiotic resistance. Therefore, when the person
exits the patient’s room, they must use a sink with non-antibacterial hand soap and wash their
hands for at least twenty seconds ensuring all parts of their hand including under their fingernails
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are properly cleaned. This practice of handwashing before interacting with the next patient will
result in the removal of the greatest amount of possible transmission between patient rooms.
Hospital Layout
Patients that are suspected or confirmed for infection with C. difficile should be placed in
a single room. This decreases the changes of the patient spreading the bacterium to their
roommate. In cases where single rooms are not available, if more than one patient has C. difficile
they should be placed in a room together. Quarantining patients to the smallest area possible will
result in an increased control of the spread of the bacterium.
Hospital Cleaning Staff Responsibilities
C. difficile is an endospore forming bacterium. It is able to survive on surfaces for weeks
to months after it was deposited there. Therefore, not only is it important that people who are
interacting directly with the patient be conscious of their actions, but those that come into contact
with the room after the patient has left and before the room is cleaned for the next patient. For
example, the staff that cleans the room must take extra precautions. The solution being used to
clean the room should be sporocidal which means that it will kill spores (Gerding et al., 2008).
Many hospital make the mistake of not using a different cleaning agent when dealing with
rooms, in which patients who had C. difficile colitis were staying. This can be a great problem
due to the fact that some common cleaning agents that hospital cleaning staff use to clean the
rooms can actually encourage sporulation of endospores (Gerding et al., 2015). For example, it
has been found that quaternary ammonium-base detergents will, in fact, encourage the
germination of endospores (Gerding et al., 2015). Therefore, it is necessary for hospitals to use
chlorine-based disinfectants or high-concentration vaporized peroxide solutions (Gerding et al.,
13

2015). It has also been found that a 1:10 dilution of concentrated sodium hyperchlorite (bleach)
is a great sporocidal solution (Gerding et al., 2015). This is a good option for hospitals as it is
not a difficult solution to make and it can be made relatively inexpensively.
However, cleaning staff must not get complacent in their cleaning routines when dealing
with rooms that have been exposed to C. difficile. The staff must thoroughly clean all bed
railings, call buttons, television remotes, or any other surface that a patient could have touched
(Gerding et al., 2015). During an outbreak in the hospital of C. difficile there should also be
meeting with management and cleaning staff in order to help the cleaning staff to better
understand the importance of cleaning the room (Gerding et al., 2015). This will help to greatly
reduce the continued spread of the bacterium.
FMT in a Pill
FMT is a good treatment for patients. However, it can be time consuming and difficult to
find donors that are good matches for the patient and to administer the FMT. Research should be
conducted in order to determine which bacteria in the FMT are causing the patient to recover
from C. difficile. The parts of the FMT that are found to be the solution that gets rid of the over
population of the C. difficile should be put into a pill. This pill will be easy to administer and
convenient for the patient and doctor. This will eliminate the need to put the patient under
anesthesia to perform a colonoscopy. It will reduce costs incurred by the patient and the time that
doctors must spending trying to combat the bacterium. Also, with a pill, there will be no
instruments that will need to be disinfected for the spores. Transmission of spores to another
patient will greatly be reduced.
Continued Care Practices
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Not only should all of these practices be applied in the hospital setting, but when a patient
gets discharged, these cleanliness practices should be continued in order to eradicate the
bacterium at the house (Gerding et al., 2015). This will keep the bacteria from spreading again
from the patient’s house to a visitor or healthcare provider that has been to their house.
At home, the patient’s restroom should be cleaned with a 1:10 dilution of concentrated
sodium hyperchlorite (bleach). Also, any other areas of the house that they come into contact
with should be cleaned. Visitors should use a restroom other than the one the patient is using if
available. Also, visitors should wear gloves and a gown when interacting with the patient. This
will form a barrier between the patient and the visitors. This practice also decreases the
probability of the visitor transmitting the bacterium to places outside of the home.
It is also suggested that only those needing to have direct contact with the patients be
admitted into their home. With technology today, there are many options to video conference
with the patient. This limits the exposure that others have to the bacterium. Until the C. difficile
colitis is resolved this should be the preferred method of interaction with the patient.
Once the patient’s symptoms have subsided, all hard surfaces in the home should be
cleaned with the 1:10 dilution of concentrated sodium hyperchlorite (bleach) in order to kill
spores that are present in the home. Once the home has been cleaned, visitors will be allowed to
visit the patient.
Further Development of Care
In order to reduce the risk of incidence of C. difficile colitis, it is necessary to research it
to gain a better understanding. Therefore, it should be necessary that culturing for C. difficile be
performed on toxin-positive stool (Cohen et al., 2013). This will allow research to be done to
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gain more information about how the bacteria are changing and insight into how to combat them.
This will also lead to the ability to better diagnosis a patient. It has been found that
approximately only 30% of hospitalized patients who have antibiotic-associated diarrhea will
have C. difficile colitis (Cohen et al., 2013). Being able to better understand the bacterium will
help to further develop testing to better identify those who are infected.
Conclusion
C. difficile colitis is a disease that can be controlled. There simply has to be education in
place in order to help physicians and patients better understand the risks of the antibiotics that
they are prescribing and taking. Also, there must be education and practices put into place about
how to maintain a clean environment so that the bacteria do not have a chance to spread from
person to person and increase the risk of more people acquiring the bacteria. As a community,
we can keep these bacteria from taking the lives of those that with a few simple practices could
have been saved.
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